research
∙
12/21/2022
Duration of and time to response in oncology clinical trials from the perspective of the estimand framework
Duration of response (DOR) and time to response (TTR) are typically eval...
share
research
∙
06/10/2022
Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions
For the analysis of a time-to-event endpoint in a single-arm or randomiz...
research
∙
03/04/2022
The Role of Occlusion: Potential Extension of the ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis for Time-to-Event Oncology Studies
The ICH E9 (R1) Estimands Guidance1 terminology does not completely addr...
research
∙
03/03/2022
Censoring and censoring mechanisms in oncology in light of the estimands framework
In oncology clinical trials with time-to-event endpoints, censoring rule...
research
∙
10/01/2020
